Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients Post author: Post published:April 18, 2024 Post category:uncategorized A trial of lixisenatide to assess its effects in early Parkinson’s disease. You Might Also Like COVID pandemic boosted food diversity and diet quality in U.S. households, study finds July 21, 2024 Study explores link between muscle strength and mental health in older adults October 10, 2024 Restoring insulin sensitivity without TZD side effects April 14, 2024